An error occurred retrieving publication content to display, please try again.
Page not found (404)
Sorry - the page you requested could not be found.
Please choose a page from the navigation or try a website search above to find the information you need.
Toolkit
Report finds that dasatinib and nilotinib appear to have statistically significant advantages in molecular and cytogenic response compared with imatinib as first-line treatments for chronic myeloid leukaemia. This finding relates to short-term (1- to 2-year) trial outcomes, and longer-term impacts on survival and other patient-relevant outcomes remain uncertain.
1 Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK
2 Matrix Evidence, Matrix Knowledge Group, London, UK
3 Department of Haematology, Royal Devon and Exeter Hospital, Exeter, UK
* Corresponding author Email: toby.pavey@pcmd.ac.uk
Funding: {{metadata.Funding}}
{{metadata.Journal}} Volume: {{metadata.Volume}}, Issue: {{metadata.Issue}}, Published in {{metadata.PublicationDate | date:'MMMM yyyy'}}
https://doi.org/{{metadata.DOI}}
Citation:{{author}}{{ (($index < metadata.AuthorsArray.length-1) && ($index <=6)) ? ', ' : '' }}{{(metadata.AuthorsArray.length <= 6) ? '.' : '' }} {{(metadata.AuthorsArray.length > 6) ? 'et al. ' : ''}}. {{metadata.JournalShortName}} {{metadata.PublicationDate | date:'yyyy'}};{{metadata.Volume}}({{metadata.Issue}})
Report Content
The full text of this issue is available as a PDF document from the Toolkit section on this page.
The full text of this issue is available as a PDF document from the Toolkit section on this page.
Responses to this report
No responses have been published.
An error has occurred in processing the XML document